Treatment of chronic chalazion and hordeolum with botulinum toxin
View Patent ↗Chalazia and hordeola are the most common lesions occurring in the human eyelid, and often recurrences are managed by surgical intervention to remove fatty inclusions within the lid with associated inflammatory reaction. The present invention provides non-surgical methods of treating chalazia, hordeola and cutaneous infections comprising the administration of compositions comprising botulinum toxin. The present invention provides methods that effectively block meibum secretion from the meibomian glands, reduce sebaceous bacterial culture media on skin, and sebaceous secretion from the glands of Zeis. Decreased production of meibum and associated fatty substances resulting from the methods of the present invention, decrease gland blockage and tissue inspissations, resulting in reduced recurrence of chalazia, hordeola and related inflammatory reactions and lesions.
1. A method of treating chalazion, comprising the step of administering a therapeutically effective amount of a composition comprising botulinum toxin to a subject suffering from chalazion, wherein the composition reduces secretion from the meibomian glands.
2. The method of claim 1 , wherein the botulinum toxin is immunotype A, B, C, D, E, F, or G.
3. The method of claim 1 , wherein the composition is administered at a dose between 0.5 and 50,000 mouse LD 50 units of botulinum toxin.
4. The method of claim 2 , wherein the composition is administered at a dose between 0.5 and 50,000 mouse LD 50 units of botulinum toxin.
5. The method of claim 1 , wherein the composition is administered by injection into the eyelid or conjunctiva.
6. The method of claim 2 , wherein the composition is administered by injection into the eyelid or conjunctiva.
7. The method of claim 3 , wherein the composition is administered by injection into the eyelid or conjunctiva.
8. The method of claim 4 , wherein the composition is administered by injection into the eyelid or conjunctiva.
9. The method of claim 1 , wherein there are at least two injection sites.
10. A method of treating hordeolum, comprising the step of administering a therapeutically effective amount of a composition comprising botulinum toxin to a subject suffering from hordeolum, wherein the composition reduces secretion from the sebaceous glands.
11. The method of claim 10 , wherein the botulinum toxin is immunotype A, B, C, D, E, F, or G.
12. The method of claim 10 , wherein the composition is administered at a dose between 0.5 and 50,000 mouse LD 50 units of botulinum toxin.
13. The method of claim 10 , wherein the composition is administered by injection into the eyelid or conjunctiva.
14. The method of claim 13 , wherein there are at least two injection sites.